|
MC4R Selective Ligand for Obesity and Alzheimer’s Disease Prevention
This technology is a novel peptide that has been shown to be a potent MC4R selective antagonist. It is a potential therapeutic for cognitive loss and obesity.
Background:
The challenges of neurodegradation, Alzheimer’s disease, and obesity have been shown to have some similar molecular signatures that contribute to disease and have thus created...
Published: 3/12/2024
|
Inventor(s): Minying Cai, Victor Hruby
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Healthcare Portfolios > Diabetes, Metabolism, Endocrinology & Obesity, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules
|
|
Selective Melanotropin 4 Ligands for Neurodegenerative Diseases
This technology is the development of ligands that selectively bind to the Melanocortin 3 Receptor (MC3R) and Melanocortin 4 Receptor (MC4R) and modulate receptor activity for neurodegenerative diseases. The melanocortin receptor ligand is bound to an MC3R and/or MC4R selective moiety, which allows the complex to cross the blood brain barrier. The ligand-moiety...
Published: 3/12/2024
|
Inventor(s): Minying Cai, Victor Hruby
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Enhanced Melanoma Cancer Prevention by Novel Melanotropins
This invention describes a method to stimulate natural production of melanin in the body. This stimulation is provided by a selective gamma-melanocyte stimulating hormone derivative, which incites the increase in melanin in the body. A natural increase confers photo protective properties without the need for UV activation, making it a safe compound.
Background:
Existing...
Published: 3/12/2024
|
Inventor(s): Minying Cai, Victor Hruby
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Biologics
|
|
Selective Melanotropin Ligands for Neurodegenerative Diseases including Parkinson's
This technology involves administering an α-melanocyte-stimulating hormone through a carrier to selective melanotropin receptor ligands to treat neurodegenerative diseases. Specifically, this technology allows melanotropin to be administered through either one or both, the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R).
Background:
There...
Published: 3/12/2024
|
Inventor(s): Minying Cai, Victor Hruby
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Drug Delivery
|
|
Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety
This invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action.
Background:
Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Minying Cai
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > Mental Health, Technology Classifications > Life Sciences > Therapeutics
|
|
Method for the Treatment of Depression and Anxiety
This technology relates to a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin. This modified version of SHU9119 can antagonize the Melanocortin 5 Receptor (MC5R), potentially enabling rapidly-acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Minying Cai, Horst Kessler
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics
|
|
Methods for the Treatment of Central Nervous System (CNS) Disorders and Mood Disorders
This technology is a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin Receptors. This modified version of SHU9119 can antagonize a Melanocortin 5 Receptor, allowing rapidly acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood disorders.
Background:
Current...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Minying Cai
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics
|
|
Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety
This technology describes a cyclic peptide modification that allows for antagonistic binding toward melanocortin 5 receptor (MC5R). Evidence links this receptor to depression and mood disorders, allowing the invention to effectively treat certain mental disorders.
Background:
SHU9119 is a peptide chain that is known to interact with melanocortin...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Minying Cai
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics
|
|
Method for the Treatment of Depression
This invention involves utilizing a composition, PG-20N, to treat depression or anxiety. It is specifically designed to treat conditions with a selective melanocortin 5 (MC5R) antagonist. Melanocortins exert many biological activities in the brain including control of feeding, grooming, hyperalgesia, social and sexual behaviors, central regulation of...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Minying Cai, Caurnel Morgan
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules
|
|
Conjugation of the MCR1 Ligand with Cytotoxic Drugs for Targeted Melanoma Therapy
University of Arizona researchers have developed a drug composition and method of cancer treatment using chemotherapeutics linked to ligands selective for uptake by melanocortin 1 receptors (MC1R) in MC1R-overexpressing melanoma. This development targets melanoma, and may be used with a wide range of cytotoxic drugs, to selectively deliver a toxic payload...
Published: 3/12/2024
|
Inventor(s): Minying Cai, Victor Hruby, Yang Zhou
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Dermatology, Technology Classifications > Healthcare Portfolios > Oncology
|
